Neonatal abstinence syndrome (NAS) is a constellation of signs of withdrawal occurring
after birth following in utero exposure to licit or illicit opioids. Despite significant research and …

Neonatal abstinence syndrome (NAS) due to in-utero opioid exposure is a growing
epidemic with significant variability in clinical presentation and severity. Currently, NAS …

Significant variability has been observed in the development and severity of neonatal
abstinence syndrome (NAS) among neonates exposed to prenatal opioids. Since maternal …

Background Use or abuse of opioids and related drugs during pregnancy increases the risk
of maternal and neonatal morbidities, including increased susceptibility to Neonatal …

Background The aim of this study was to identify genetic variants associated with NAS
through a genome-wide association study (GWAS) and estimate a Polygenic Risk Score …

Neonatal abstinence syndrome (NAS) refers to cadre of withdrawal manifestations in infants
born to mothers who used illicit and licit substances during pregnancy. The increasing …

Opioid use in pregnancy has increased dramatically over the past decade. Since prenatal
opioid use is associated with numerous obstetrical and neonatal complications, this now has …

Importance Neonatal abstinence syndrome, which occurs as a result of in utero opioid
exposure, affects between 6.0 and 20 newborns per 1000 live US births. There is substantial …

In this nonsystematic review and opinion, including articles primarily selected from PubMed,
we examine the pharmacological and nonpharmacological treatments of neonatal …

Background Neonatal abstinence syndrome (NAS) includes an array of symptoms impacting
opioid-exposed newborns (OEN) owing to postnatal withdrawal from in utero substance …